Department of Medical Physics, Osaka Heavy Ion Therapy Center, Osaka, Japan.
Department of Carbon Ion Radiotherapy, Osaka University Graduate School of Medicine, Osaka, Japan.
Med Phys. 2024 Oct;51(10):7393-7403. doi: 10.1002/mp.17309. Epub 2024 Jul 15.
In carbon ion radiation therapy (CIRT) the predominant method of irradiation is raster scanning, called dose driven continuous scanning (DDCS) by Hitachi, allowing for continuous synchrotron extraction. The reduction in irradiation time is highly beneficial in minimizing the impact of patient and target movement on dose distribution. The RF knock out (RFKO) slow-extraction method is commonly used for beam on/off control. When the Hitachi synchrotron receives a beam off signal the control system stops the RFKO and after some delay time (t-delay) during which the beam intensity declines, a high-speed steering magnet (HSST) is used to sweep the remaining beam from isocenter to a beam dump for safety reasons. Mayo Clinic Florida (MCF) will use a very short delay of the HSST operation from the RFKO beam OFF signal to minimize the delay time and delayed dose. MCF clinical beam intensity, a tenfold increase over HIMAK, is still less than 100 mMU/ms (approximately 4.9 × 10 pps for 430 MeV/u).
The rapid beam off control (RBOC) proposed for MCF is associated with the occurrence of flap dose (FD), which refers to the asymmetric shoulder of the spot dose profile formed from the beam bent by HSST deviating from its planned spot position on the isocenter plane. In this study, we quantitatively assessed FD, proposed a treatment planning system (TPS) implementation using a flap spot (FS) and evaluated its impact on dose distribution.
The experiments were conducted at the Osaka Heavy Ion Therapy Center (HIMAK) varying the t-delay from 0.01 to 1 ms in a research environment to simulate the MCF RBOC. We studied the dependence of FD position on beam transport and its dependence on energy and beam intensity. FD was generated by delivering 10000 continuous spots on the central axis that are occasionally triggered by an external 10 Hz gate signal. Measurements were conducted using an oscilloscope, and the nozzle's spot position monitor (SPM) and dose monitor (DM).
All spot profile data were corrected for the gain of the SPM's beam intensity dependence. FD was determined by fitting the (SPM) Profile data to a double Gaussian. The position of the FS was found to be transport path dependent, with FS occurring on the opposite sides of the scanning x-direction for vertical and horizontal ports, respectively, as predicted by transport calculations. It was observed that the FD increases with beam intensity and did not exhibit a significant dependence on energy. The effect of FD on treatment planning is shown to have no significant dose impact on the organs at risk (OARs) near the target for clinical beam intensities and a modest increase for very high intensities.
Using HIMAK in research mode the implications are that the FD has no clinical impact on the clinical CIRT beam intensities for MCF and maybe planned for higher intensities by incorporating FS into the TPS to predict the modest increased dose to OARs. A method for commissioning and quality assurance of FD has been proposed.
在碳离子放射治疗(CIRT)中,主要的辐照方法是光栅扫描,日立称之为剂量驱动连续扫描(DDCS),允许连续同步加速器提取。照射时间的缩短非常有利于最大限度地减少患者和目标运动对剂量分布的影响。RF 消光(RFKO)慢速提取方法通常用于束流开启/关闭控制。当日立同步加速器接收到束流关闭信号时,控制系统会停止 RFKO,并在延迟时间(t-delay)后,束流强度下降,高速转向磁铁(HSST)用于将剩余的束流从等中心扫到束流dump,以确保安全。佛罗里达梅奥诊所(MCF)将使用 HSST 操作的非常短的 RFKO 束流关闭延迟时间,以最小化延迟时间和延迟剂量。MCF 的临床束流强度是 HIMAK 的十倍,但仍低于 100mMU/ms(对于 430MeV/u,约为 4.9×10pps)。
为 MCF 提出的快速束流关闭控制(RBOC)与瓣状剂量(FD)有关,FD 是指由 HSST 弯曲的束流偏离等中心平面上计划的斑点位置而形成的斑点剂量分布的不对称肩部。在这项研究中,我们定量评估了 FD,提出了一种使用瓣状光斑(FS)的治疗计划系统(TPS)实现方法,并评估了它对剂量分布的影响。
在大阪重离子治疗中心(HIMAK)进行了实验,在研究环境中改变 t-delay 从 0.01 到 1ms,以模拟 MCF 的 RBOC。我们研究了 FD 位置对束流传输的依赖性及其对能量和束流强度的依赖性。通过在中央轴上连续发射 10000 个光斑来产生 FD,偶尔由外部 10Hz 门信号触发。使用示波器进行测量,并使用喷嘴的光斑位置监视器(SPM)和剂量监视器(DM)进行测量。
所有光斑轮廓数据都根据 SPM 束流强度依赖性的增益进行了校正。通过将(SPM)轮廓数据拟合到双高斯函数来确定 FD。发现 FS 的位置与传输路径有关,对于垂直和水平端口,FS 分别出现在扫描 x 方向的相反侧,这与传输计算的预测一致。结果表明,FD 随束流强度的增加而增加,与能量没有明显的依赖性。FD 对治疗计划的影响表明,对于临床束流强度,FD 对靶区附近的危及器官(OARs)没有显著的剂量影响,对于非常高的强度则有适度的增加。
在 HIMAK 研究模式下,这意味着 FD 对 MCF 的临床 CIRT 束流强度没有临床影响,并且通过将 FS 纳入 TPS 中以预测 OARs 适度增加的剂量,可能会为更高的强度进行计划。已经提出了 FD 的调试和质量保证方法。